

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adjusted diluted EPS

Venlo, the Netherlands, April 27, 2026 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary results for the first quarter of 2026 that achieve the outlook for adjusted diluted earnings per share (EPS). Sales results were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

QIAGEN also updates its full-year 2026 outlook for reduced net sales growth and lower adjusted diluted EPS.

For Q1 2026, preliminary net sales were \$492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER growth. Adjusted diluted EPS are expected to be \$0.54 on a reported basis and \$0.54 CER, in line with the outlook.

QIAGEN's growth pillars together grew 4% CER compared to Q1 2025. Sample technologies delivered 9% CER growth compared with Q1 2025, and 3% CER growth excluding the Parse acquisition, supported by demand for automated consumables and instrument placements. QIAcuity digital PCR delivered double-digit CER sales growth on higher consumables and instrument sales over the year-ago period. QIAGEN Digital Insights (QDI) posted solid single-digit gains led by clinical bioinformatics. QIAstat-Dx sales declined 1% CER as expected against tough prior-year results. Consumables sales rose despite a weaker respiratory season on double-digit CER growth from recently launched Gastrointestinal and Meningitis panels in the U.S., while instrument placements continued at a good level.

QuantiFERON sales declined 5% CER from Q1 2025, mainly due to a significant decline in immigration testing demand in the United States and the Middle East. Trends remained solid in other patient testing groups. QIAGEN now expects QuantiFERON full-year 2026 sales to be unchanged at CER compared with 2025 sales of \$503 million.

QIAGEN reduces its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include headwinds from reduced QuantiFERON immigration testing demand, sustained caution among U.S. Life Sciences customers and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least \$2.43 CER (previously at least \$2.50 CER). QIAGEN expects stronger growth trends in the second half of 2026, supported by the end of headwinds from the discontinuation of NeuMoDx and Dialunox, benefits from recent and planned product launches, sequential improvement in QuantiFERON sales and contributions from the Parse acquisition tracking ahead of the original target for 2026.

For Q2 2026, QIAGEN expects net sales to decline approximately 2% CER from \$534 million in Q2 2025. Adjusted diluted EPS are expected to be at least \$0.60 CER compared with \$0.60 in Q2 2025.

QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands

Ad hoc



ISIN: NL0015001WM6

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:

Investor Relations

Daniel Wendorff, Tel: +49 2103 29 11322; ir@qiagen.com